NEW YORK, NY / ACCESSWIRE / July 26, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Bloom Energy Corporation (NYSE: BE)
Investors Affected : on behalf of all persons who purchased or otherwise acquired Bloom Energy common stock pursuant or traceable to Bloom Energy’s July 2018 IPO.
A class action has commenced on behalf of certain shareholders in Bloom Energy Corporation. The complaint alleges that Bloom Energy's Registration Statement was materially misleading as it failed to disclose known events and trends that were severely affecting the Company’s business and that made investment in Bloom Energy significantly riskier than presented in the Registration Statement. In particular, the Registration Statement failed to disclose that the Company was experiencing material construction delays. These construction delays would cause system deployments (or “acceptances” as Defendants referred to them) to fall significantly below even the low end of the Company’s previously announced guidance.
While the Registration Statement purported to warn of risks that “may arise,” which could materially affect the Company, in actuality these material negative events were already occurring. As a result, the representations and purported risk disclosures were false and misleading because, by the time of the IPO, construction delays had already impacted or would soon impact Bloom Energy’s ability to deliver acceptances in line with its guidance.
Shareholders may find more information at https://securitiesclasslaw.com/securities/bloom-energy-corporation-loss-submission-form/?id=2629&from=1
Ra Medical Systems, Inc. (NYSE: RMED)
Investors Affected : stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.
A class action has commenced on behalf of certain shareholders in Ra Medical Systems, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/ra-medical-systems-inc-loss-submission-form/?id=2629&from=1
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
Investors Affected : on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares (“ADS”) between August 4, 2017 and May 10, 2019
A class action has commenced on behalf of certain shareholders in Teva Pharmaceutical Industries Ltd. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.
Shareholders may find more information at https://securitiesclasslaw.com/securities/teva-pharmaceutical-industries-ltd-loss-submission-form/?id=2629&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com: